Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406315 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 255
- Enrollment target
NCT00406315 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 255 participants.
The verdict
NCT00406315, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 255 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.
Interventions
- DRUG ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406315
The ClinicalTrials.gov registry entry for NCT00406315 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ziprasidone is the first listed.
NCT00406315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00406315 about?
NCT00406315 is a clinical study titled "Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone". The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerabili...
What is the current status of trial NCT00406315?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 255 participants. The study started on 2006-11. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00406315?
The interventions under investigation include: ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00406315?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.